Soluble p185HER-2 in patients with malignant bone tumours
| Autor: | M. Koschat, Klemens Trieb, T. Pfandlsteiner, Gerold Holzer, Rainer Kotz, H. Noske |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Pathology Clinical variables Adolescent Receptor ErbB-2 medicine.medical_treatment Bone Neoplasms Sarcoma Ewing Bone tumours Internal medicine Biomarkers Tumor medicine Humans In patient Child Osteosarcoma Chemotherapy Predictive marker business.industry Hematology Middle Aged medicine.disease Predictive value Pediatrics Perinatology and Child Health Female Sarcoma business |
| Zdroj: | Pediatric Blood & Cancer. 44:163-166 |
| ISSN: | 1545-5017 1545-5009 |
| DOI: | 10.1002/pbc.20217 |
| Popis: | Background This study was initiated to test the hypothesis that soluble p185HER-2 could be of value as a diagnostic or predictive marker for patients with malignant bone tumours. Procedure Sera of 35 patients with high-grade malignant osteosarcoma (n = 27) and Ewing Sarcoma (n = 8) were tested at the time of diagnosis by ELISA and compared with sera of controls (n = 38) and clinical data. Results In patients with osteosarcoma and Ewing Sarcoma, levels of sp185HER-2 did not differ significantly from levels in controls. These results were irrespective of the type of tumour, survival chemotherapy or other clinical variables. Conclusion p185HER-2 serum levels do not appear to be of diagnostic or predictive value for differentiation of high-grade osteosarcoma and Ewing Sarcoma. © 2004 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text